Want to see IN:TORNTPHARM full AI Analyst Report?
Top Page
Torrent Pharmaceuticals Ltd
(TORNTPHARM)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹5,519.00
▲(11.27% Upside)
Action:Upgraded
Date:05/24/26
The score is driven primarily by strong financial performance (growth, profitability, and generally solid cash generation) and supportive technical trend/momentum. These positives are tempered by a demanding valuation (high P/E and low yield) and a balance-sheet transparency risk stemming from the sharp FY2026 asset increase.
Positive Factors
Revenue Growth and Profitability
Sustained revenue expansion alongside stronger net margins indicates effective portfolio execution and operating leverage. This supports durable earnings growth across Torrent’s branded-generic therapy areas, although product mix and cost trends remain important.
Negative Factors
FY2026 Asset Transparency Risk
The unusually large asset increase makes year-over-year financial comparisons less reliable and raises uncertainty about the composition and quality of the balance sheet. Limited supporting detail could complicate assessment of sustainable returns and capital efficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Profitability
Sustained revenue expansion alongside stronger net margins indicates effective portfolio execution and operating leverage. This supports durable earnings growth across Torrent’s branded-generic therapy areas, although product mix and cost trends remain important.
Read all positive factors
Torrent Pharmaceuticals Ltd (TORNTPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.86T
Dividend Yield0.31%
Average Volume (3M)7.49K
Price to Earnings (P/E)76.0
Beta (1Y)0.47
Revenue Growth32.85%
EPS Growth8.94%
CountryIN
Employees20,341
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)64.44
Shares Outstanding380,354,250
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio5.00
Price to Book (P/B)17.02
Price to Sales (P/S)10.22
P/FCF Ratio73.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68.65
Revenue Forecast (FY)₹196.39B
Torrent Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across k...
How the Company Makes Money
Torrent Pharmaceuticals primarily makes money by selling finished-dose pharmaceutical formulations (branded generics) to healthcare channels (pharmacies, hospitals, and distributors) in India and abroad. In its core India business, revenue is driv...
Torrent Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
72
Positive
Cash Flow
76
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 156.15B | 139.80B | 113.17B | 105.62B | 94.64B | 84.19B |
| Gross Profit | 90.56B | 68.24B | 84.33B | 77.75B | 66.36B | 58.81B |
| EBITDA | 50.26B | 32.57B | 37.19B | 35.00B | 28.81B | 21.41B |
| Net Income | 21.81B | 21.63B | 19.11B | 16.56B | 12.45B | 7.77B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 443.12B | 149.90B | 150.61B | 150.12B | 131.00B |
| Cash, Cash Equivalents and Short-Term Investments | 23.55B | 23.70B | 6.91B | 10.04B | 7.23B | 5.83B |
| Total Debt | 0.00 | 150.25B | 32.02B | 40.22B | 53.68B | 40.70B |
| Total Liabilities | -175.85B | 267.27B | 73.99B | 82.04B | 88.14B | 71.47B |
| Stockholders Equity | 175.85B | 83.89B | 75.91B | 68.56B | 61.98B | 59.53B |
Cash Flow | ||||||
| Free Cash Flow | 8.42B | 19.55B | 19.74B | 28.33B | 17.94B | 16.00B |
| Operating Cash Flow | 10.38B | 26.32B | 25.85B | 32.66B | 23.68B | 18.03B |
| Investing Cash Flow | -2.14B | -127.49B | -5.40B | -1.68B | -24.15B | -1.97B |
| Financing Cash Flow | -8.26B | 105.78B | -22.98B | -27.80B | 770.00M | -17.81B |
Torrent Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ₹4.56T | 37.74 | ― | 0.82% | 11.41% | 16.62% | |
72 Outperform | ₹980.26B | 29.57 | ― | 0.69% | -0.92% | -41.75% | |
71 Outperform | ₹1.86T | 75.99 | ― | 0.30% | 32.85% | 8.94% | |
69 Neutral | ₹1.00T | 18.20 | ― | 0.76% | 28.19% | 49.25% | |
59 Neutral | ₹979.63B | 48.17 | ― | 0.04% | 13.75% | 6.23% | |
57 Neutral | ₹1.12T | 24.96 | ― | 0.09% | 21.11% | -1.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,880.50
1,241.97
34.13%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,175.00
-101.51
-7.95%
IN:LUPIN
Lupin Limited
2,193.00
242.74
12.45%
IN:MANKIND
Mankind Pharma Ltd.
2,372.00
-185.45
-7.25%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,900.90
259.20
15.79%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,120.00
97.52
9.54%
Torrent Pharmaceuticals Ltd Corporate Events
Torrent Pharmaceuticals completes electronic dispatch of postal ballot notice
Aug 6, 2026
Torrent Pharmaceuticals Ltd has completed the electronic dispatch of its Postal Ballot Notice to shareholders whose email IDs were registered as of July 31, 2026, in line with the Companies Act, 2013 and SEBI Listing Regulations. The company also ...
Torrent Pharma Announces Completion of Independent Director’s Term
Aug 1, 2026
Torrent Pharmaceuticals Ltd., a publicly listed Indian pharmaceutical manufacturer and marketer, operates under SEBI’s regulatory framework on both BSE and NSE, serving healthcare markets while maintaining compliance-focused governance struc...
Torrent Pharma posts Q1 FY27 earnings call recording online
Jul 30, 2026
Torrent Pharmaceuticals Ltd has uploaded the audio recording of its conference call with analysts and investors discussing financial results for the quarter ended June 30, 2026, to the company’s website, in line with SEBI disclosure regulati...
Torrent Pharma Completes Amalgamation of J. B. Chemicals and Revises Capital Structure
Jul 8, 2026
Torrent Pharmaceuticals Ltd has completed the amalgamation of J. B. Chemicals Pharmaceuticals Ltd into Torrent Pharma following approval by the National Company Law Tribunal, Ahmedabad Bench. Certified copies of the tribunal’s order and the...
Torrent Pharma Completes Amalgamation of J. B. Chemicals and Updates Capital Structure
Jul 8, 2026
Torrent Pharmaceuticals Ltd has completed the court-approved amalgamation of J. B. Chemicals Pharmaceuticals Ltd, with the scheme becoming effective on July 8, 2026, following filings with the Registrar of Companies in Ahmedabad. As a result, J. ...
Torrent Pharma files assured sustainability report for FY 2025-26
Jun 1, 2026
Torrent Pharmaceuticals has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year, integrating it into the annual report and making it available on its website. The report details the company’s ESG fr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.